<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02846974</url>
  </required_header>
  <id_info>
    <org_study_id>107952</org_study_id>
    <nct_id>NCT02846974</nct_id>
  </id_info>
  <brief_title>Calibration and Validation of High Quality Low-Cost 3D Printed Pulse Oximeter</brief_title>
  <official_title>Calibration and Validation of High Quality Low-Cost 3D Printed Pulse Oximeter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>London Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Al Shifa Hospital, Gaza</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Western Ontario, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <brief_summary>
    <textblock>
      Pulse oximetry is a vital tool in the rapid and non-invasive assessment of emergency&#xD;
      patients, providing a continuous estimate of hemoglobin saturation in arterial blood.&#xD;
      Unfortunately, the costs of these devices are prohibitive and reduce availability in smaller&#xD;
      centres and poor countries, putting millions of patients in danger of easily treatable and&#xD;
      preventable conditions. With current rapid prototyping technologies such as 3D printing, it&#xD;
      is possible to create a very inexpensive pulse oximeter that meets or exceeds the gold&#xD;
      standard. The goal of this study is to develop, validate and certify a pulse oximeter that&#xD;
      measures hemoglobin, carboxyhemoglobin and methemoglobin. This pulse oximeter will be&#xD;
      certified with Health Canada, and then released under the Open Hardware License (OHL), such&#xD;
      that hospitals and ministries of health in rural and impoverished communities in Canada and&#xD;
      internationally would have easy access to these devices.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 25, 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pulse oximetry reading</measure>
    <time_frame>1 hour</time_frame>
    <description>Pulse oximetry readings will be taken over the span of an hour to calibrate the device</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arterial blood gas</measure>
    <time_frame>1 hour</time_frame>
    <description>Arterial blood gases will be taken to create a proper calibration curve along with the device's readings.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Pulse Oximetry</condition>
  <condition>Free and Open Source</condition>
  <arm_group>
    <arm_group_label>Calibration cohort</arm_group_label>
    <description>In this cohort, approximately 30 subjects will be put through a controlled desaturation study with controlled hypoxia until they arrive at approximately SpO2 = 70%. Measurements will be taken via arterial catheterization to resolve proper values to calibrate the device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Validation cohort</arm_group_label>
    <description>In this cohort, approximately 250 patients will have a single pulse oximetry reading taken using the novel device and a gold standard device to ensure accurate validation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pulse oximeter</intervention_name>
    <description>A pulse oximeter will be used for calibration</description>
    <arm_group_label>Calibration cohort</arm_group_label>
    <arm_group_label>Validation cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study has 2 Phases. In Phase 1, healthy, non-smoking adult volunteers greater than 18&#xD;
        years of age are invited to participate. In Phase 2, all adult (&gt;18) non-critical patients&#xD;
        and healthy community volunteers visiting the emergency department at Victoria Hospital and&#xD;
        University Hospital are eligible to participate.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - This study has 2 Phases. In Phase 1, healthy, non-smoking adult volunteers greater than&#xD;
        18 years of age are invited to participate. In Phase 2, all adult (&gt;18) non-critical&#xD;
        patients and healthy community volunteers visiting the ED at VH and UH are eligible to&#xD;
        participate.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Potential participants will be excluded based on the following criteria:&#xD;
&#xD;
        Phase 1:&#xD;
&#xD;
          -  greater than 70 years of age,&#xD;
&#xD;
          -  current smokers,&#xD;
&#xD;
          -  previous history of cardiac disease (e.g., atrial fibrillation, myocardial infarction,&#xD;
             congestive heart failure),&#xD;
&#xD;
          -  history of moderate or severe asthma,&#xD;
&#xD;
          -  history of seizures,&#xD;
&#xD;
          -  history of stroke or transient ischemic attack&#xD;
&#xD;
          -  pregnant women&#xD;
&#xD;
          -  Patients with any active pulmonary disease such as pneumonia&#xD;
&#xD;
          -  Individuals who are unwilling to participate or are less than 18 years old&#xD;
&#xD;
          -  Those who are unable to consent&#xD;
&#xD;
        Phase 2&#xD;
&#xD;
          -  Critical patients will be excluded from participating&#xD;
&#xD;
          -  Individuals who are unwilling to participate or are less than 18 years old will be&#xD;
             excluded&#xD;
&#xD;
          -  Those who are unable to consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tarek Loubani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>London Health Sciences Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tarek loubani, MD</last_name>
    <phone>+15196858500</phone>
    <phone_ext>54970</phone_ext>
    <email>tarek@tarek.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tarek Loubani, MD</last_name>
      <phone>+15196858500</phone>
      <phone_ext>54970</phone_ext>
      <email>tarek@tarek.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 23, 2016</study_first_submitted>
  <study_first_submitted_qc>July 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2016</study_first_posted>
  <last_update_submitted>January 23, 2020</last_update_submitted>
  <last_update_submitted_qc>January 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lawson Health Research Institute</investigator_affiliation>
    <investigator_full_name>Tarek Loubani, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pulse Oximetry</keyword>
  <keyword>Free and Open Source</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

